Literature DB >> 27895755

Inhibitory effects of Chinese nutritional herbs in isogenic breast carcinoma cells with modulated estrogen receptor function.

Nitin Telang1, Guo Li2, Meena Katdare3, Daniel Sepkovic4, Leon Bradlow4, George Wong5.   

Abstract

In estrogen receptor (ER)+ MCF-7 cells, ER represents a ligand-activated transcription factor, and 17β-estradiol (E2) represents its physiological ligand. Maintenance of the human breast carcinoma-derived MCF-7 cells with 0.7% serum selected a proliferative sub-population of E2-responsive cells with transiently non-functional ER due to limited availability of E2. Culture of MCF-7 cells in the presence of either 0.7% serum, <1 nM E2 or 0.7% serum + 20 nM E2 selected isogenic cells with either non-functional ER (ER-NF) or functional ER (ER-F) phenotype. The two phenotypes responded to the growth-promoting effects of E2 and to the growth-inhibitory effects of the selective ER modulator tamoxifen, indicating retention of E2 responsiveness. Comparative dose-response experiments with Chinese nutritional herbs on ER-NF and ER-F cells identified the inhibitory concentration (IC)50 values for these herbs, while the IC50 ratios for the ER-NF:ER-F phenotypes facilitated their rank ordering in terms of efficacy. Out of the 11 efficacious herbs tested, five herbs exhibited ER-F > ER-NF inhibitory activity, four exhibited ER-F = ER-NF inhibitory activity and two exhibited ER-NF > ER-F inhibitory activity. Extracts from representative herbs, Lycium barbarum bark, Epimedium grandiflorum and Cornus officinalis, from each of the three groups inhibited anchorage-independent growth, induced G1 or G2/M arrest and/or apoptosis, and generated anti-proliferative E2 metabolites. The differential growth inhibition in ER-NF and ER-F phenotypes, together with the mechanistic efficacy of representative herbs, identified potential leads for their efficacy on ER+ and/or ER- breast cancer.

Entities:  

Keywords:  growth inhibition; isogenic breast carcinoma cells; nutritional herbs

Year:  2016        PMID: 27895755      PMCID: PMC5104215          DOI: 10.3892/ol.2016.5197

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  In Vitro and In Vivo Modulation of Growth Regulation in the Human Breast Cancer Cell Line MCF-7 by Estradiol Metabolites.

Authors: 
Journal:  Breast Cancer       Date:  1999-04-02       Impact factor: 4.239

2.  Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro.

Authors:  Michael J Campbell; Bobbi Hamilton; Mark Shoemaker; Mary Tagliaferri; Isaac Cohen; Debasish Tripathy
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

Review 3.  Biological determinants of endocrine resistance in breast cancer.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

4.  In vitro model systems for the study of hormone-dependent human breast cancer.

Authors:  M E Lippman; C K Osborne; R Knazek; N Young
Journal:  N Engl J Med       Date:  1977-01-20       Impact factor: 91.245

Review 5.  Efforts to combine endocrine and chemotherapy in the management of breast cancer: do two and two equal three?

Authors:  M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

6.  Putative cancer-initiating stem cells in cell culture models for molecular subtypes of clinical breast cancer.

Authors:  Nitin Telang
Journal:  Oncol Lett       Date:  2015-10-06       Impact factor: 2.967

7.  Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells.

Authors:  Meena Katdare; Michael Osborne; Nitin T Telang
Journal:  Int J Oncol       Date:  2002-10       Impact factor: 5.650

8.  Abnormal oxidative metabolism of estradiol in women with breast cancer.

Authors:  J Schneider; D Kinne; A Fracchia; V Pierce; K E Anderson; H L Bradlow; J Fishman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

9.  The use of complementary and alternative medicines among patients with locally advanced breast cancer--a descriptive study.

Authors:  Lucy K Helyer; Stephen Chin; Betty K Chui; Barbara Fitzgerald; Sunil Verma; Eileen Rakovitch; George Dranitsaris; Mark Clemons
Journal:  BMC Cancer       Date:  2006-02-21       Impact factor: 4.430

10.  Screening to Identify Commonly Used Chinese Herbs That Affect ERBB2 and ESR1 Gene Expression Using the Human Breast Cancer MCF-7 Cell Line.

Authors:  Jen-Hwey Chiu; Chun-Ju Chang; Jing-Chong Wu; Hui-Ju Liu; Che-Sheng Wen; Chung-Hua Hsu; Jiun-Liang Chen; Ling-Ming Tseng; Wei-Shone Chen; Yi-Ming Shyr
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-27       Impact factor: 2.629

View more
  9 in total

1.  Growth inhibitory efficacy of Cornus officinalis in a cell culture model for triple-negative breast cancer.

Authors:  Nitin T Telang; Hareesh B Nair; George Y C Wong
Journal:  Oncol Lett       Date:  2019-03-21       Impact factor: 2.967

2.  Growth inhibitory efficacy and anti-aromatase activity of Tabebuia avellanedae in a model for post-menopausal Luminal A breast cancer.

Authors:  Nitin Telang; Hareesh B Nair; George Y C Wong
Journal:  Biomed Rep       Date:  2019-10-03

3.  Growth inhibitory efficacy of natural products in a model for triple negative molecular subtype of clinical breast cancer.

Authors:  Nitin Telang
Journal:  Biomed Rep       Date:  2017-08-01

4.  The nutritional herb Epimedium grandiflorum inhibits the growth in a model for the Luminal A molecular subtype of breast cancer.

Authors:  Nitin T Telang; Gou Li; Meena Katdare; Daniel W Sepkovic; H Leon Bradlow; George Y C Wong
Journal:  Oncol Lett       Date:  2017-02-13       Impact factor: 2.967

Review 5.  Stem Cell Models for Cancer Therapy.

Authors:  Nitin Telang
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

Review 6.  The Divergent Effects of Ovarian Steroid Hormones in the MCF-7 Model for Luminal A Breast Cancer: Mechanistic Leads for Therapy.

Authors:  Nitin T Telang
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

Review 7.  Corni Fructus: a review of chemical constituents and pharmacological activities.

Authors:  Yu Dong; Zhe-Ling Feng; Hu-Biao Chen; Fu-Sheng Wang; Jia-Hong Lu
Journal:  Chin Med       Date:  2018-06-25       Impact factor: 5.455

8.  Exploring the Pharmacological Mechanism of Danzhi Xiaoyao Powder on ER-Positive Breast Cancer by a Network Pharmacology Approach.

Authors:  Kailin Yang; Liuting Zeng; Jinwen Ge
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-05       Impact factor: 2.629

Review 9.  Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer.

Authors:  Nitin T Telang; Hareesh B Nair; George Y C Wong
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.